Approaches to Precision-based Anticoagulation management in the critically Ill

被引:2
|
作者
Dager, William [1 ,2 ,3 ,7 ]
Trujillo, Toby [4 ,5 ]
Gilbert, Brian [6 ]
机构
[1] Univ Calif Davis, Med Ctr, Sacramento, CA USA
[2] Univ Calif San Francisco, Sch Pharm, San Francisco, CA USA
[3] Univ Calif Sacramento, Sch Med, Sacramento, CA USA
[4] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
[5] Univ Colorado Hosp, Anticoagulat Cardiol, Aurora, CO USA
[6] Wesley Med Ctr, Wichita, KS USA
[7] 4880 French Creek Rd, Shingle Springs, CA 95682 USA
来源
PHARMACOTHERAPY | 2023年 / 43卷 / 11期
关键词
anticoagulation; critical care; drugs; individualized; management; precision-based; special populations; thrombosis; HEPARIN-INDUCED THROMBOCYTOPENIA; PRACTICAL MANAGEMENT; THROMBOPROPHYLAXIS; GUIDANCE; THERAPY; PLASMA;
D O I
10.1002/phar.2868
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Anticoagulant therapy is commonly associated with a high incidence of avoidable adverse events, especially in the acute care setting. This has led to several initiatives by key national health care stakeholders, including specific attention to The Joint Commission's National Patient Safety Goals, to improve anticoagulation management. The subject of special populations has long been identified as challenging by clinicians with the use of anticoagulants. This is driven in part by numerous variables that can contribute to hard outcomes such as bleeding, thrombosis, length of stay, hospital re-admission, morbidity, and mortality. Despite the notable effort to improve the use of anticoagulants with numerous clinical trials, guidelines, guidance statements, and other sources of published evidence, notable difficulties continue to challenge practitioners in managing this class of medications. This is especially the case with very diverse critically ill populations where countless variables exist, many of which were never explored in trials or have historically been frequently excluded. Trials evaluating anticoagulation therapy often can only account for small portions of variables that may affect thrombosis and hemostasis, and study methods often do not reflect the constantly changing dynamic conditions seen in unique critically ill patients. Clinicians providing care to the numerous critically ill populations are faced with conditions that lead to relatively small therapeutic windows, which makes designing safe optimal anticoagulation management plans difficult when dealing with complex patients and mechanical support devices. The approach to crafting a successful management plan for anticoagulant therapy must incorporate the numerous variables that are continuously assessed and revised during the patient's time in the intensive care unit. We explore considerations and approaches when developing, assessing, and implementing an individualized or precision-based management plan that involves the use of anticoagulants in the critically ill. The skills and thought process provided will assist clinicians in managing this unique, variable, and challenging population.
引用
收藏
页码:1221 / 1236
页数:16
相关论文
共 50 条
  • [1] Developing precision-based multidisciplinary pharmacotherapy management plans in the critically ill
    Dager, William E.
    [J]. PHARMACOTHERAPY, 2023, 43 (11): : 1102 - 1111
  • [2] Advancing precision-based antimicrobial dosing in critically ill patients
    Menino O. Cotta
    Jeffrey Lipman
    Jan De Waele
    [J]. Intensive Care Medicine, 2023, 49 : 324 - 326
  • [3] Advancing precision-based antimicrobial dosing in critically ill patients
    Cotta, Menino O.
    Lipman, Jeffrey
    De Waele, Jan
    [J]. INTENSIVE CARE MEDICINE, 2023, 49 (03) : 324 - 326
  • [4] Management of Anticoagulation in the Critically Ill Patient
    Toale, Katy M.
    [J]. CRITICAL CARE NURSING CLINICS OF NORTH AMERICA, 2013, 25 (04) : 471 - +
  • [5] Precision-based modeling approaches for necrotizing enterocolitis
    Kovler, Mark L.
    Sodhi, Chhinder P.
    Hackam, David J.
    [J]. DISEASE MODELS & MECHANISMS, 2020, 13 (06)
  • [6] Precision-based approaches to delirium in critical illness: A narrative review
    Ankravs, Melissa J. J.
    McKenzie, Cathrine A. A.
    Kenes, Michael T. T.
    [J]. PHARMACOTHERAPY, 2023, 43 (11): : 1139 - 1153
  • [7] Precision-based Boosting
    Nikravan, Mohammad Hossein
    Movahedan, Marjan
    Zilles, Sandra
    [J]. THIRTY-FIFTH AAAI CONFERENCE ON ARTIFICIAL INTELLIGENCE, THIRTY-THIRD CONFERENCE ON INNOVATIVE APPLICATIONS OF ARTIFICIAL INTELLIGENCE AND THE ELEVENTH SYMPOSIUM ON EDUCATIONAL ADVANCES IN ARTIFICIAL INTELLIGENCE, 2021, 35 : 9153 - 9160
  • [8] Anticoagulation in critically ill patient
    Fries, Dietmar
    [J]. WIENER MEDIZINISCHE WOCHENSCHRIFT, 2009, 159 (19-20) : 487 - 491
  • [9] Argatroban anticoagulation in critically ill patients
    Beiderlinden, Martin
    Treschan, Tanja A.
    Goerlinger, Klaus
    Peters, Juergen
    [J]. ANNALS OF PHARMACOTHERAPY, 2007, 41 (05) : 749 - 754
  • [10] THE OXYGEN DELIVERY CONSUMPTION CONTROVERSY - APPROACHES TO MANAGEMENT OF THE CRITICALLY ILL
    RUSSELL, JA
    PHANG, PT
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (02) : 533 - 537